EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

A perspective on precision therapeutics in polycystic ovary syndrome: integrating multi-omics, AI-driven stratification, and emerging biologics

Philippe Pinton

Frontiers in Endocrinology · 2026

DOI: 10.3389/fendo.2026.1787902 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Frontiers in Endocrinology, 2026. Verfasst von Philippe Pinton. Beteiligte Einrichtung: Health & Life Sciences, Shiroito Co. Ltd, Tokyo, Japan. Hauptthemen laut MEDLINE: Polycystic Ovary Syndrome, Precision Medicine, Artificial Intelligence, Biological Products. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Polycystic ovary syndrome (PCOS) is one of the most prevalent and heterogeneous disorders in reproductive endocrinology, contributing to substantial reproductive, metabolic, and psychological morbidity. Despite major advances in genomics, neuroendocrinology, and systems biology, translation into disease-modifying therapies remains limited. This Perspective argues for a strategic shift toward precision medicine, supported by molecular subtyping, multi-omics profiling, and artificial intelligence (AI). These tools now enable biologically informed patient stratification and the identification of novel therapeutic targets. We highlight emerging strategies - including anti-Müllerian hormone (AMH) neutralization, neuroendocrine modulators, metabolic agents, and next-generation biologics - and discuss the regulatory, ethical, and operational considerations required to accelerate innovation. A coordinated, multi-disciplinary approach integrating computational analytics, biomarker-driven endpoints, and patient-centered outcomes is essential to close the longstanding gap between scientific potential and clinical reality.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Polycystic Ovary SyndromePrecision MedicineArtificial IntelligenceBiological ProductsHumansFemaleMultiomicsGenomics

Stichwörter der Autor:innen

AMHartificial intelligencebiologicsdisease-modifying-therapiesmulti-omicspatient stratificationpolycystic ovary syndromeprecision medicine

Substanzen

Biological Products

Autor:innen und Institutionen

  • Health & Life Sciences, Shiroito Co. Ltd, Tokyo, Japan.

Zitieren

APA

Pinton, P. (2026). A perspective on precision therapeutics in polycystic ovary syndrome: integrating multi-omics, AI-driven stratification, and emerging biologics. Frontiers in Endocrinology. https://doi.org/10.3389/fendo.2026.1787902

Vancouver

Pinton P. A perspective on precision therapeutics in polycystic ovary syndrome: integrating multi-omics, AI-driven stratification, and emerging biologics. Frontiers in Endocrinology. 2026. doi:10.3389/fendo.2026.1787902

BibTeX
@article{Pinton2026,
  author = {Pinton, Philippe},
  title = {A perspective on precision therapeutics in polycystic ovary syndrome: integrating multi-omics, AI-driven stratification, and emerging biologics},
  journal = {Frontiers in Endocrinology},
  year = {2026},
  doi = {10.3389/fendo.2026.1787902}
}
Kostenlos starten →